Boswellia

About Boswellia

Boswellia, known as Indian Frankincense or Shallaki in Ayurveda, is a resinous tree that weeps tears of aromatic gum from wounds in its bark, and those tears have been healing human wounds for over 5,000 years. The resin is the same substance known as frankincense, sacred across multiple civilizations from ancient Egypt to biblical Israel to modern Catholic and Orthodox churches. When the Magi brought frankincense to the Christ child, they were offering one of the ancient world's most valued medicines.

In Ayurveda, Shallaki holds a prominent position as a supreme anti-inflammatory herb with a particular affinity for asthi dhatu (bone and cartilage tissue) and the musculoskeletal system. Its energetic profile is remarkable, with four of the six rasas present (bitter, pungent, sweet, astringent) and a cooling virya, it achieves the rare status of being effectively tridoshic. This broad rasa spectrum and balanced energetics allow it to reduce inflammation without the energetic extremes that make most anti-inflammatory herbs suitable for only one or two doshas.

The resin is harvested by making incisions in the bark of Boswellia serrata trees during the dry season. The milky-white oleoresin exudes and hardens into translucent, aromatic tears over 2-3 weeks. Several Boswellia species produce medicinal resins. B. serrata (Indian), B. carterii (East African), and B. sacra (Arabian), with B. serrata having the most extensive research base for internal medicinal use.

What are the traditional uses of Boswellia?

The Charaka Samhita classifies Shallaki among herbs that treat vatasonitha (joint disorders) and shotahara (anti-inflammatory herbs). Sushruta describes it in formulations for vranaropana (wound healing), shotahara (reducing swelling), and vedanasthapana (pain relief). It is included in the classical Ayurvedic formula Yogaraja Guggulu for deep-seated joint and musculoskeletal conditions. Vagbhata in the Ashtanga Hridayam recommends Shallaki for medoroga (metabolic disorders) and prameha (urinary conditions), indicating its broader metabolic applications.

In Unani medicine, frankincense (Kundur) is classified as a muqawwi dimagh (brain tonic) and musakkin (sedative). It was used for improving memory, treating ulcers, and strengthening the mind, a use that modern research on boswellic acids' neuroprotective effects has begun to validate.

The burning of frankincense in temples and churches across multiple religions may have therapeutic roots beyond symbolism. Modern research has confirmed that burning frankincense produces incensole acetate, a compound that activates TRPV3 channels in the brain and produces anxiolytic and antidepressant effects. The ancient practice of creating sacred spaces with frankincense smoke was, perhaps knowingly, creating pharmacologically active healing environments.

What does modern research say about Boswellia?

Frankincense resin owes much of its anti-inflammatory profile to boswellic acids, particularly AKBA (3-O-acetyl-11-keto-β-boswellic acid), which selectively inhibits 5-lipoxygenase — the enzyme that converts arachidonic acid into leukotrienes, highly potent inflammatory mediators. Safayhi and colleagues established this mechanism in 1992 using rat peritoneal neutrophils and human platelets, reporting an IC50 near 1.5 µM for AKBA in vitro^[1]. The clearest clinical translation has been in osteoarthritis of the knee. A 2008 double-blind RCT of 5-Loxin (an AKBA-enriched extract) in 75 patients over 90 days found that the 250 mg arm produced significant improvements in pain and function as early as day 7^[2].

Beyond joint pain, Boswellia serrata has been studied in conditions involving inflammatory edema of the central nervous system. In a 2011 placebo-controlled pilot trial of 44 patients receiving radiotherapy for brain tumors, 4,200 mg/day of the resin produced >75% reduction in cerebral edema in 60% of the treated group versus 26% on placebo (P=.023) — a striking signal, though the trial was small and explicitly framed as a pilot^[3]. In relapsing-remitting multiple sclerosis, the 2018 SABA phase IIa trial reported reductions in disease activity over an open-label, baseline-controlled design^[4]. The MS finding is preliminary; without a placebo arm, it should be read as a hypothesis-generating signal rather than confirmation of efficacy.

The inflammatory bowel disease literature is the part most often misrepresented, and it deserves to be told straight. Two trials by Gupta and colleagues in active disease showed frankincense performing comparably to sulfasalazine: 82% remission versus 75% in ulcerative colitis (1997)^[5], and 70% versus 40% in chronic colitis (2001)^[6]. A separate 2001 trial in active Crohn's disease found Boswellia extract H15 non-inferior to mesalazine^[7]. But the largest and most rigorous test — Holtmeier's 2011 double-blind, placebo-controlled trial of the resin for maintaining remission in Crohn's — found no efficacy, with 59.9% on boswellia versus 55.3% on placebo staying in remission (P=0.85)^[8]. The honest read: small active-disease trials versus older comparator drugs look promising, the one well-powered maintenance trial was negative, and most RCTs are modest in size, often single-site, and frequently industry-sponsored; convergence across endpoints is the meaningful signal.

How does Boswellia affect the doshas?

For Pitta types, boswellia is an ideal anti-inflammatory. Its cooling virya directly addresses pitta's inflammatory tendencies, while its ability to inhibit 5-LOX targets the specific inflammatory pathway most active in pitta conditions. Pitta individuals with joint inflammation, inflammatory bowel symptoms, skin inflammation, or inflammatory headaches can use boswellia as a primary anti-inflammatory herb with confidence.

For Kapha types, boswellia's pungent and bitter rasas and its ability to resolve swelling and clear channels make it valuable for kapha-type joint conditions, the heavy, swollen, stiff joints that accumulate fluid and ama. It moves stuck kapha out of the joints and channels while reducing the inflammation that drives kapha's tendency toward chronic swelling.

For Vata types, boswellia addresses the inflammatory component of vata joint conditions while its sweet rasa and cooling virya prevent the drying that most anti-inflammatory herbs cause. Vata arthritis often has both a degenerative (drying) and inflammatory component, boswellia addresses the inflammation without worsening the degeneration. Combine with ashwagandha and guggulu for comprehensive vata musculoskeletal support.

Which tissues and channels does Boswellia affect?

What is the recommended dosage for Boswellia?

Standardized extract (30% boswellic acids): 300-500 mg, 2-3 times daily. AKBA-enriched extract: 100-250 mg daily. Raw resin: 1-3 grams, 2-3 times daily. Churna (powder): 1-3 grams with warm water or milk, twice daily. Clinical studies have typically used 300-400 mg of standardized extract, 3 times daily. Effects may be noticeable within 1-2 weeks but optimal results typically require 4-8 weeks of consistent use.

What herbs combine well with Boswellia?

Turmeric and Boswellia together create the most well-studied natural anti-inflammatory combination in existence. Turmeric's curcumin inhibits NF-kB and COX-2, while boswellia's AKBA inhibits 5-LOX. Together they block all three major inflammatory pathways, prostaglandins, leukotrienes, and the NF-kB master switch. Clinical studies using this combination have shown remarkable results for osteoarthritis, with some trials demonstrating superior outcomes to the pharmaceutical celecoxib.

With Guggulu, boswellia creates the classical Ayurvedic formula Shallaki Guggulu, a highly effective traditional preparations for chronic joint diseases. Guggulu penetrates deep tissues and scrapes ama from the channels (lekhana), while boswellia reduces inflammation at the site. This combination addresses both the toxic accumulation and the inflammatory response in joint disease.

Boswellia combined with Ashwagandha and Ginger creates a comprehensive musculoskeletal formula. Boswellia provides targeted anti-inflammatory action, ashwagandha rebuilds depleted tissues and nervous system function (important in chronic pain), and ginger enhances circulation to the joints and improves bioavailability of the other herbs.

When is the best season to use Boswellia?

Boswellia is valuable year-round for individuals with chronic inflammatory conditions, joint disease does not follow seasonal patterns. However, inflammatory conditions often flare during seasonal transitions, particularly during Sharad (autumn) when accumulated pitta manifests as inflammatory symptoms. Increasing boswellia during these transitions can help manage seasonal flares.

During Varsha (monsoon), when joint pain traditionally worsens due to dampness and barometric changes, boswellia combined with warming herbs like ginger and guggulu provides targeted joint support.

In Hemanta and Shishira (winter), when vata increases and cold stiffness compounds joint conditions, boswellia's anti-inflammatory action remains relevant but should be paired with warming, circulation-enhancing herbs. During Grishma (summer), boswellia's cooling nature aligns well with the season.

How do I choose quality Boswellia?

Seek extracts standardized to boswellic acid content, minimum 30%, ideally 40% or higher for AKBA-enriched preparations. The source species matters: Boswellia serrata has the most clinical research. Indian-sourced Shallaki from established Ayurvedic suppliers generally maintains high quality standards. For raw resin, look for translucent, amber-colored tears with a strong, clean, woody-citrus aroma. Avoid dark, opaque resin that smells rancid. For essential oil, Boswellia carterii and Boswellia sacra are the most valued species. Sustainability is a growing concern, some Boswellia populations are over-harvested, so sustainably sourced products are preferred. Store resin and extracts in cool, dry conditions, boswellic acids are relatively stable but degrade with prolonged heat exposure.

Affiliate link — we earn a small commission at no extra cost to you.